Citations

Showing 10 of 108081 citations.

Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy
Landen, Jaren W., Cohen, Sharon , Billing, Clare B., Cronenberger, Carol, Styren, Scot, Burstein, Aaron H. , Sattler, Catherine, Kantarci, Kejal , Schwartz, Pamela F., Duggan, William, Zhao, Qinying, Sprenger, Ken, Bednar, Martin M., Binneman, Brendon, Lee, Jae‐Hong , Jack, Clifford R. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | May 11, 2017 | Volume: 3 | Issue: 3 | Pages: 339-347

10.1016/j.trci.2017.04.003 | PMID 29067341 Get It

Abstract Introduction Multiple intravenous doses of ponezumab, an anti‐amyloid antibody, were evaluated in subjects with mild‐to‐moderate Alzheimer's disease (AD). Methods In part A, 77 subjects were randomized to ponezumab 0.1, 0.5, or 1 mg/kg (75 treated) and 26 to placebo (24 treated). In part B, 63 subjects were randomized and treated with ponezumab 3 or 8.5 mg/kg and 32 with placebo. Subjects received 10 infusions over 18 months and were followed for 6 months thereafter. Results Ponezumab was generally safe and well tolerated. Most common adverse events were fall (16.7% ponezumab, 21.4% placebo), headache (13.8%, 21.4%), and cerebral microhemorrhage (13.8%, 19.6%). Plasma ponezumab increased dose‐dependently with limited accumulation. Cerebrospinal fluid penetration was low. Plasma Aβ 1–x and Aβ 1–40 showed robust increases, but cerebrospinal fluid biomarkers showed no dose response. Ponezumab had no effects on cognitive/functional outcomes or brain volume. Conclusions Multiple‐dose ponezumab was generally safe, but not efficacious, in mild‐to‐moderate AD.
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium
Moghadasi, Setareh , Vreeswijk, Maaike P.G. , Janssen, Linda AM, Borg, Åke , Ehrencrona, Hans , Paulsson-Karlsson, Ylva, Wappenschmidt, Barbara , Engel, Christoph , Gehrig, Andrea, Hansen, Thomas van Overeem , Thomassen, Mads , Jensen, Uffe Birk , Kruse, Torben A., Ejlertsen, Bent , Gerdes, Anne‐Marie , Pedersen, Inge Søkilde , Caputo, Sandrine M. , Couch, Fergus J., Hallberg, Emily J., Ouweland, Ans MW van den, Collée, Margriet J., Teugels, Erik , Adank, Muriel A. , Luijt, Rob B. van der , Mensenkamp, Arjen R. , Oosterwijk, Jan C., Blok, Marinus J. , Janin, Nicolas, Claes, Kathleen , Tucker, Kathy , Viassolo, Valeria , Eccles, Diana , Devilee, Peter , Asperen, Christi J. van , Goldgar, David E., Gómez, E. , Meeks, Huong , Janssen, Linda A.M., Arnold, Norbert , Collée, Margriet , Toland, Amanda Ewart , Spurdle, Amanda B. , Eccles, Diana , Vreeswijk, Maaike P G , Claes, Kathleen B M , Ehrencrona, Hans , van der Luijt, Rob B , Engel, Christoph , van Asperen, Christi J , Gómez-García, Encarna B , Hansen, Thomas van Overeem , Devilee, Peter

Mayo Clinic

Journal of Medical Genetics | May 11, 2017 | Volume: 55 | Issue: 1 | Pages: 15-20

10.1136/jmedgenet-2017-104560 | PMID 28490613 Get It

Background We previously showed that the BRCA1 variant c.5096G>A p.Arg1699Gln (R1699Q) was associated with an intermediate risk of breast cancer (BC) and ovarian cancer (OC). This study aimed to assess these cancer risks for R1699Q carriers in a larger cohort, including follow-up of previously studied families, to further define cancer risks and to propose adjusted clinical management of female BRCA1*R1699Q carriers. Methods Data were collected from 129 BRCA1*R1699Q families ascertained internationally by ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) consortium members. A modified segregation analysis was used to calculate BC and OC risks. Relative risks were calculated under both monogenic model and major gene plus polygenic model assumptions. Results In this cohort the cumulative risk of BC and OC by age 70 years was 20% and 6%, respectively. The relative risk for developing cancer was higher when using a model that included the effects of both the R1699Q variant and a residual polygenic component compared with monogenic model (for BC 3.67 vs 2.83, and for OC 6.41 vs 5.83). Conclusion Our results confirm that BRCA1*R1699Q confers an intermediate risk for BC and OC. Breast surveillance for female carriers based on mammogram annually from age 40 is advised. Bilateral salpingo-oophorectomy should be considered based on family history.
Towards the Future Development of an Electrochemical Continuous Multimarker Biosensor for Enhanced Glycemic Management
Lin, Chi, Probst, David , Honikel, Mackenzie M. , Belle, Jeffrey T. La , La Belle, Jeffrey T, Malkoc, Aldin

Mayo Clinic

Journal of Diabetes Science and Technology | May 11, 2017 | Volume: 11 | Issue: 5 | Pages: 1053-1054

10.1177/1932296817707543 | PMID 28490199 Get It

Endoscopic Resection of Sinonasal Mucosal Melanoma has Comparable Outcomes to Open Approaches
Miglani, Amar , Patel, Samir H. , Hinni, Michael L., Hayden, Richard E. , Kosiorek, Heidi , Lal, Devyani

Mayo Clinic

American Journal of Rhinology & Allergy | May 11, 2017 | Volume: 31 | Issue: 3 | Pages: 200-204

10.2500/ajra.2017.31.4435 | PMID 28490408 Get It

Background Endoscopic endonasal resection (EER) of sinonasal mucosal melanoma (SMM) is a newer surgical alternative to traditional external and/or open resection (OR). Studies on long-term outcomes are necessary to validate EER for this aggressive sinonasal malignancy. Objective To compare outcomes of EER versus OR in SMM. Methods A case series of patients who underwent surgical resection of SMM at a tertiary-care institution (2000–2015) was studied retrospectively. Demographics, tumor site and stage, surgical approach, surgical margin status, local control, and survival were compared between those who underwent EER and OR. Results Twenty-two patients met inclusion criteria. Nine underwent EER and 13 underwent OR. The mean age in the EER and OR groups was similar, 78.7 and 72.3 years, respectively. Two-thirds of patients were women (EER, 66.7%; OR, 61.5%). The nasal cavity was the most common primary tumor site (EER, 77.8%; OR, 84.6%). The local tumor stage in both groups was similar, with the majority of cases being T4 (EER, 55.6%; OR, 61.5%; p = 0.99). Negative margins were achieved in all EERs and in 69.2% of ORs. Median follow-up was 25.0 months for the overall group (range, 1.7–172.9 months), 32.6 months (range, 3.4–58.7 months) for EER and 14.1 months (range, 1.7–172.9 months) for OR cohorts. The 5-year overall survival was statistically similar in both groups (EER, 53.3%; OR, 22.7%; p = 0.214) as was disease-free survival (EER, 55.6%; OR, 22.8%; p = 0.178). Local control, however, was significantly higher in the EER cohort (EER, 85.7%; OR, 37.6%; p = 0.026). Conclusion In carefully selected patients with sinonasal melanoma, endoscopic surgery with an experienced team may offer comparable survival and improved local control over open surgery. Prospective, multicentered studies with larger cohorts are needed to validate these results.
Attitudes, Beliefs, Practices, and Concerns Among Clinicians Prescribing Opioids in a Large Academic Institution
Ebbert, Jon O. , Philpot, Lindsey M. , Clements, Casey M. , Lovely, Jenna K. , Nicholson, Wayne T. , Jenkins, Sarah M. , Lamer, Tim J. , Gazelka, Halena M. , Philpot, Lindsey M

Mayo Clinic

Pain Medicine | May 10, 2017 | Volume: 19 | Issue: 9 | Pages: 1790-1798

10.1093/pm/pnx140 | PMID 29177439 Get It

Estimating the impact of adopting the revised United Kingdom acetaminophen treatment nomogram in the U.S. population
Levine, Michael , Stellpflug, Sam, Pizon, Anthony F. , Traub, Stephen J., Vohra, Rais, Wiegand, Timothy J. , Traub, Nicole A., Tashman, David, Desai, Shoma , Chang, Jamie , Nathwani, D, Thomas, Stephen, Stellpflug, Samuel J. , Thomas, Stephen H. , Traub, Stephen, Traub, Nicole, Thomas, Stephen H

Mayo Clinic

Clinical Toxicology | May 10, 2017 | Volume: 55 | Issue: 6 | Pages: 569-572

10.1080/15563650.2017.1291945 | PMID 28489461 Get It

Comparative Toxicity of Purified Human Eosinophil Granule Cationic Proteins for Schistosomula of Schistosoma Mansoni *
Ackerman, Steven J. , Gleich, Gerald J. , Butterworth, A , Loegering, David A., Richardson, Brian A.

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | May 10, 2017 | Volume: 34 | Issue: 4 | Pages: 735-745

10.4269/ajtmh.1985.34.735 | PMID 4025686 Get It

Executive summary of the SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease
Sorajja, Paul , Borlaug, Barry A. , Dimas, V. Vivian , Forfia, Paul R. , Givertz, Michael M., Kapur, Navin K. , Naidu, Srihari S. , Sorajja, Paul , Fang, James C. , Givertz, Michael M. , Kern, Morton J. , Borlaug, Barry A

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 10, 2017 | Volume: 89 | Issue: 7 | Pages: 1294-1299

10.1002/ccd.27036 | PMID 28489324 Get It

SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease
Sorajja, Paul , Borlaug, Barry A. , Dimas, Vasiliki V., Fang, James C., Forfia, Paul R. , Givertz, Michael M. , Kapur, Navin K. , Naidu, Srihari S. , Dimas, V. Vivian , Sorajja, Paul , Dimas, Vasiliki V., Kern, Morton J. , Borlaug, Barry A

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 10, 2017 | Volume: 89 | Issue: 7 | Pages: No page available

10.1002/ccd.26888 | PMID 28489331 Get It

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic‐based dosing of irinotecan, oxaliplatin, and capecitabine as first‐line therapy for patients with advanced small bowel adenocarcinoma
McWilliams, Robert R. , Foster, Nathan R. , Mahoney, Michelle R., Smyrk, Thomas C. , Ames, Matthew M. , Horvath, Laura E., Hobday, Timothy J. , Jatoi, Aminah , Meyers, Jeffrey P., Jatoi, Aminah , Murray, Joseph A. , Schneider, Daniel , Goetz, Matthew P. , McWilliams, Robert R

Mayo Clinic

Cancer | May 10, 2017 | Volume: 123 | Issue: 18 | Pages: 3494-3501

10.1002/cncr.30766 | PMID 28493308 Get It

BACKGROUNDOxaliplatin in combination with either 5‐fluorouracil or capecitabine is commonly used as first‐line therapy for patients with small bowel adenocarcinoma. The addition of irinotecan improves survival in other gastrointestinal tumors but at the cost of hematologic toxicity. The authors performed a phase 2 cooperative group study (North Central Cancer Treatment Group N0543, Alliance) using genotype‐dosed capecitabine, irinotecan, and oxaliplatin (gCAPIRINOX), with dosing assigned based on UDP glucuronosyltransferase family 1 member A1 (UGT1A1) genotype to test: 1) whether the addition of irinotecan would improve outcomes; and 2) whether UGT1A1 genotype‐based dosing could optimize tolerability.METHODSPreviously untreated patients with advanced small bowel adenocarcinoma received irinotecan (day 1), oxaliplatin (day 1), and capecitabine (days 2‐15) in a 21‐day cycle and were dosed with gCAPIRINOX according to UGT1A1*28 genotypes (6/6, 6/7, and 7/7).RESULTSA total of 33 patients (17 with the 6/6 genotype, 10 with the 6/7 genotype, and 6 with the 7/7 genotype) were enrolled from October 2007 to November 2013; 73% were male, with a mean age of 64 years (range, 41‐77 years). Location of the primary tumor included the duodenum (58%), jejunum (30%), and ileum (9%). The regimen yielded a confirmed response rate of 37.5% (95% confidence interval, 21%‐56%), with a median progression‐free survival of 8.9 months and a median overall survival of 13.4 months. Neither hematologic toxicity (grade ≥3 in 52.9%, 30.0%, and 33.3%, respectively, of the 6/6, 6/7, and 7/7 genotype groups) nor tumor response rate (41.2%, 33%, and 33%, respectively) were found to differ significantly by UGT1A1 genotype.CONCLUSIONSUGT1A1 genotype‐directed dosing (gCAPIRINOX) appears to be feasible with favorable rates of hematologic toxicity compared with prior 3‐drug studies in unselected patients. Larger studies would be needed to determine the regimen's comparability to oxaliplatin and capecitabine (CapeOx) alone or if response/toxicity differs among patients with different UGT1A1 genotypes. Cancer 2017;123:3494‐501. © 2017 American Cancer Society.